Population Health
Source: Population Health Management
Programmatic integrated approaches have been used successfully and cost-effectively to manage various chronic conditions. The incorporation of rtCGM in similar integrated approaches to diabetes management presents an opportunity to improve quality outcomes and reduce costs on a population level. This publication details the evidence to suggest it may be time to support broader adoption to incorporate the use of rtCGM.
Learn More
In 2021, NCQA and HL7 hosted the fifth annual Digital Quality Summit (DQS) that convened stakeholders within six distinct “tracks” – each track exploring a different subset of healthcare. Track 6 of the Digital Quality Summit featured five breakout sessions that covered topics such as Continuous Glucose Monitoring (CGM), diabetes distress, digital measurement and measure concepts related to diabetes care, optimal care for individuals with type 1 and type 2 diabetes, NCQA’s own Diabetes Recognition Program, and more.
The Rethinking Diabetes Care in the Digital Age white paper contains findings from track 6 of the Digital Quality Summit and is broken down into the following sections:
1. Importance of Measurement in Diabetes Care beyond HbA1c and Depression
2. Optimal Diabetes Care Management and Continuous Glucose Monitoring
3. Behavioral Aspects in Diabetes Care and Diabetes Distress
4. Health Equity in Diabetes Care Management
5. Driving Improvements in Diabetes Care and the Diabetes Recognition Program
Learn MorePresented by:
Daniel DeSalvo, MD
Assistant Professor of Pediatrics in the Section of Diabetes and Endocrinology
Baylor College of Medicine/Texas Children’s Hospital
Houston TX
In diverse and underserved populations research shows there are racial and ethnic disparities in diabetes outcomes. Disparities in diabetes technology use has the greatest influence on glycemic disparities between Black, Hispanic and Non-Hispanic White individuals. A study recently published in Diabetes Care found that lower socio-economic status was associated with lower rates of diabetes technology use and higher levels of A1C. Importantly, this gap in technology has widened over time. Data published from the T1D exchange, shows that across all age groups, individuals that use continuous glucose monitoring (CGM) have lower A1C levels compared to those who don’t use CGM.
This webinar will highlight the improvements in glycemic and psychosocial outcomes, along with best practices from recent research findings that support the use of CGM in diverse populations.
Learn More
Expert: (Formerly) Vice President Clinical Strategy and Programs and Industry Relations, MagellanRx Management (Currently Chief Clinical Officer, Cooperative Benefits Group)
Summary: In this video interview Dr. Dunn discusses best practices and considerations for payers when they consider moving CGM coverage to the pharmacy benefit, application of utilization management, and more.